2 Problématiques méthodologiques
4 REFERENCES
[1] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34 10.1136/bmj.315.7109.629 [9310563]
[2] Villar J, Carroli G, Belizán JM. Predictive ability of meta-analyses of randomised controlled trials. The Lancet 1995;345:772–76 10.1016/s0140-6736(95)90646-0 [7891492]
[3] LeLorier J, Grégoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New Engl J Med 1997;337:536–42 10.1056/NEJM199708213370806 [9262498]
[4] Cappelleri JC, Ioannidis JP, Schmid CH, et al. Large trials vs meta-analysis of smaller trials: how do their results compare? JAMA 1996;276:1332–38 ; [8861993]
[5] Meta-analysis under scrutiny. The Lancet 1997;350:675 ; [9291895]
[6] Carrigan G, Whipple S, Capra WB, et al. Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. Clin Pharmacol Ther 2020;107:369–77 10.1002/cpt.1586 [31350853]
[7] Cranney A, Welch V, Adachi JD, et al. Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev 2001:CD003376 10.1002/14651858.CD003376 [11687195]
[8] Izcovich A, Peiris S, Ragusa M, et al. Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin's suggested benefits are mainly based on potentially biased results. Journal of Clinical Epidemiology 2022;144:43–55 10.1016/j.jclinepi.2021.12.018 [34933115]
[9] Tierney JF, Fisher DJ, Vale CL, et al. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLOS Medicine 2021;18:e1003629 10.1371/journal.pmed.1003629 [33956789]
[10] Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 2003;362:772–76 10.1016/S0140-6736(03)14284-5 [13678870]
[11] McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet 2003;362:767–71 10.1016/S0140-6736(03)14283-3 [13678869]
[12] Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet 2003;362:777–81 10.1016/S0140-6736(03)14285-7 [13678871]
[13] Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 2003;362:759–66 10.1016/s0140-6736(03)14282-1 [13678868]
[14] Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021;326:499–518 10.1001/jama.2021.11330 [34228774]
[15] Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med 2020;383:546–57 10.1056/NEJMoa1917246 [32757523]
[16] Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022;28:591–98 10.1038/s41591-022-01707-4 [35210595]
